ClinicalTrials.gg
Status unknownNCT05092802Updated May 3, 2022

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

A Phase 2 interventional study of HLX208 in Brain Tumor, Primary, sponsored by Shanghai Henlius Biotech. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies in Brain Neoplasms with a site in China — 72 open to participants now, 83 under way, 6 of them phase 3. Brain Neoplasms · China.

Planned enrollment
92nd of 142
40 · median 60
Started
2021
with 12 others
Phase 2
60 of 179
19 open now
Registered
87th of 179
by date

Among the 179 studies in Brain Neoplasms with a site in China, this one is the 92nd largest by planned enrollment of the 142 interventional ones that give a count, is one of 13 that started in 2021, is one of 60 in phase 2, and was the 87th registered.

Brain Neoplasms

2,442 studies on the registry are indexed under Brain Neoplasms; 543 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

72 of the 179 studies in Brain Neoplasms with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 427 Brain Neoplasms studies recruiting now, 287 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Brain Neoplasms with a site in China, or all of them as a file.
02

Study summary

An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation

03

Conditions studied

  • Brain Tumor, Primary

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age>=18Y
  • Good Organ Function
  • Expected survival time ≥ 3 months
  • primary brain tumors with BRAF mutation that have been diagnosed
  • Unable to receive surgery/radiotherapy, or have treatment failed after surgery/radiotherapy
  • score 0-1;

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with BRAF inhibitors or MEK inhibitors
  • A history of other within two years, except for cured cervical carcinoma in situ, basal cell carcinoma of the skin, adenocarcinoma in situ of the lung, or tumors that do not require interventional treatment after radical surgery
  • Severe active infections requiring systemic anti-infective therapy
  • Other anti-tumor treatments, such as chemotherapy, targeted therapy, or radiation therapy (except palliative radiation therapy), may be given during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    HLX208

    Drug: HLX208

Interventions

06

What researchers measure

Primary outcomes

  1. ORR

    Objective response rate(assessed by independent radiological review committee (IRRC) based on the RANO

    Time frame: from first dose to the last patient was followed up for 6 month

Secondary outcomes

  1. PFS

    Progression-free survival(PFS):assessed by IRRC and the investigator based on the RANO

    Time frame: from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),an average of about 1 year

  2. DOR

    Duration of response

    Time frame: from the first occurrence of a documented CR or PR (whichever recorded earlier) to the time of first documented disease progression or death (whichever occurs first),an average of about 1 year

  3. OS

    Overall survival

    Time frame: from the first dose to the time of death due to any cause,an average of about 2 year

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital Affiliated to Shandong first medical University
    Jinan, Shandong 250117, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for May 2023, 17 months after the start.

Of 44 industry-sponsored phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 17 months is below that.

Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2021
First posted
Oct 26, 2021
StartActual
Dec 23, 2021
Primary completionEst.
May 30, 2023
CompletionEst.
May 30, 2024
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05092802
Responsible party
Sponsor
First posted
Oct 26, 2021
Start date
Dec 23, 2021
Primary completion
May 30, 2023 (estimated)
Completion
May 30, 2024 (estimated)
Last update
May 3, 2022

Study contacts

Jinming Yu
Contact
sdyujinming@126.com
0531-67626819
Zhehai Wang
Contact
ywb234@126.com
0531-67626073
Jinming Yu
principal investigator · Shandong Cancer Hospital and Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BRAF V600E Inhibitor HLX208

Start the discussion